Libraries of genetic packages comprising novel HC CDR3 designs

• US 9,873,957 B2
• Filed: 03/13/2009
• Issued: 01/23/2018
• Est. Priority Date: 03/13/2008
• Status: Active Grant

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Dyax Corporation (Shire plc)
• Inventors: Ladner, Robert C.
• Primary Examiner(s): BOESEN, CHRISTIAN C
• Application Number:
  US12/922,153
• Publication Number:
  US 20110118147A1
• Time in Patent Office: 3,238 Days
• Field of Search: None
• CPC Class Codes: C07K 16/005 constructed by phage libraries
• CPC Class Codes: C07K 16/1275 from Streptococcus (G)
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C40B 40/08 Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• CPC Class Codes: C40B 50/06 Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.

Claims

1. A method of diversifying a library, the method comprising

(i) obtaining a focused library of DNA plasmids or genetic packages comprising the DNA plasmids, the focused library comprising a plurality of variegated DNA molecules, each of which comprises a DNA sequence that encodes an antibody heavy chain variable domain having both frame work (FW) regions and complementary determining regions (CDR), wherein each antibody heavy chain variable domain comprises antibody heavy chain FW1, antibody heavy chain CDR1, antibody heavy chain FW2, antibody heavy chain CDR2, antibody heavy chain FW3, antibody heavy chain CDR3 and antibody heavy chain FW4 in a DNA molecule arranged in the orientation of FW1-CDR1-FW2-CDR2-FW3-CDR3-FW4, wherein the plurality of the variegated DNA molecules collectively encode a population of HC CDR3 regions that contain CDR3 regions having

(a) 3, 4, or 5 amino acids in length,

(b) 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 amino acids in length, or

(c) 6 to 20 amino acids in length, inclusive,

wherein the HC CDR3 regions in the focused library contain greater than 40% Tyr (Y) or Ser (S) residues,

wherein the HC CDR3 of the focused library comprises amino acids from a diversified D region or fragment thereof or an extended JH region,

wherein the variegated DNA molecules each comprise a human germline V_H gene as the FW1, FW2 and FW3 regions, and

wherein the diversity of the focused library is biased towards the natural diversity of heavy chain CDR3s of found in the human antibody family antibodies, both in sequence and in length;

and

(ii) mutagenizing the focused library of DNA plasmids or genetic packages to produce a diversified library.

2. The method of claim 1, wherein the mutagenizing comprises error-prone PCR.

3. The method of claim 1, wherein the mutagenizing comprises wobbling.

4. The method of claim 1, wherein the mutagenizing comprises dobbling.

5. The method of claim 1, wherein the HC CDR3s of the focused library comprise a D region or a fragment thereof.

6. The method of claim 5, wherein the D region is selected from the group consisting of D2-2(RF 2), D2-8(RF 2), D2-15(RF 2), D2-21(RF 2), D3-16(RF 2), D3-22 (RF 2), D3-3 (RF-2), D3-9 (RF 2), D3-10 (RF 2), D1-26 (RF 3), D4-11 (RF 2), D4-4 (RF 2), D5-5 (RF 3), D5-12 (RF 3), D5-18 (RF 3), D6-6 (RF1), D6-13 (RF 1), and D6-19 (RF 1).

7. The method of claim 5, wherein the D region comprises one or more cysteine (Cys) residues and the one or more Cys residues are held constant.

8. The method of claim 5, wherein the HC CDR3s comprise one or more filling codons between FR3 and the D region and each filling codon is individually NNK, TMY, TMT, or TMC.

9. The method of claim 5, wherein the HC CDR3s comprise one or more filling codons between the D region and JH and each filling codon is individually NNK, TMY, TMT, or TMC.

10. The method of claim 1, wherein the plurality of variegated DNA molecules comprises diversity in the HC CDR1, or HC CDR2.

11. The method of claim 10, wherein the focused library further comprises a plurality of variegated DNA molecules, each of which encodes a light chain and the library comprises diversity in the light chains.

12. The method of claim 1, wherein greater than 50% of the population of HC CDR3 regions in (a) are 3, 4, or 5 amino acids in length.

13. The method of claim 1, wherein the population of HC CDR3 regions set forth in (b) contain CDR3 regions having 23, 24, or 25 amino acids in length.

14. The method of claim 1, wherein the population of HC CDR3 regions set forth in (b) contain CDR3 regions having 33, 34, or 35 amino acids in length.